Plastic Surgery Prior Auth: Reconstruction vs Cosmetic

The Cosmetic vs. Reconstructive Distinction in Prior Authorization

No distinction matters more in plastic surgery billing and prior authorization than the line between cosmetic and reconstructive procedures. Payers define reconstructive surgery as procedures performed to correct abnormal structure of the body caused by congenital defects, developmental abnormalities, trauma, infection, tumors, or disease — and where the purpose is to improve function or create a normal appearance. Cosmetic procedures, by contrast, are performed to reshape normal structures to improve the patient's appearance and self-esteem and are explicitly excluded from coverage under most commercial health plans.

This distinction creates prior authorization complexity because many procedures exist in both categories depending on patient-specific clinical circumstances. Blepharoplasty is cosmetic when performed to improve eyelid appearance and reconstructive when redundant eyelid skin occludes the visual field. Rhinoplasty is cosmetic for appearance change and reconstructive for functional nasal obstruction. Breast reduction is elective for most commercial plans but covered when the Schnur scale criteria are met. Understanding the specific clinical threshold that transforms a cosmetic procedure into a reconstructive one — by payer — is the core competency your prior auth team must develop.

For every plastic surgery prior auth submission, the record must contain: the operative plan with specific procedure and CPT code(s), objective clinical findings supporting the reconstruction classification (photographs, visual field testing, measurements), ICD-10 diagnosis codes that reflect the underlying pathology rather than merely the anatomical finding, documentation of any conservative management attempted, and a letter of medical necessity signed by the treating plastic surgeon. Missing any of these elements from an initial submission guarantees either a denial or a request for additional information — both of which delay the patient's care and create administrative rework.

Post-Mastectomy Breast Reconstruction: Immediate vs. Delayed, Implant vs. Flap

Post-mastectomy breast reconstruction is the highest-revenue reconstructive case category in most plastic surgery practices, and it is governed by a unique federal mandate — the Women's Health and Cancer Rights Act (WHCRA) — that requires coverage by any health plan covering mastectomy. Despite the mandate, prior authorization is required by virtually every commercial payer and Medicare Advantage plan.

Reconstructive approach affects the prior auth documentation package significantly. Immediate reconstruction (reconstruction performed in the same operative session as the mastectomy) requires coordination with the general or breast surgeon who is performing the mastectomy — the plastic surgeon's prior auth request must reference the mastectomy authorization and document the coordinated surgical plan. Delayed reconstruction (performed weeks to years after mastectomy) requires documentation of the original mastectomy date, the pathology report, any adjuvant therapy received (radiation significantly complicates implant-based reconstruction and supports flap-based approaches), and the current tissue quality of the mastectomy site.

For implant-based reconstruction (CPT 19340 immediate tissue expander placement; 19342 delayed; 19357 tissue expander; 19361–19380 for exchange and revision), document: the mastectomy extent (total vs. skin-sparing vs. nipple-sparing), tissue thickness and perfusion at the mastectomy flap, and the planned two-stage protocol (expander followed by permanent implant exchange). Most commercial payers authorize the two-stage process together; some require a separate auth for the exchange (Stage 2, CPT 19342 or 19380).

For autologous flap reconstruction (DIEP: CPT 19364; TRAM: CPT 19367–19369; latissimus dorsi: CPT 19361), the clinical justification for flap versus implant must be explicit: radiation to the chest wall (relative contraindication for implant), inadequate skin/soft tissue envelope, patient preference after informed discussion of implant vs. autologous options, or prior implant failure. DIEP flap documentation must specifically note that perforator vessels were identified (by CTA angiogram, CPT 74175 or 74178, or MRA, CPT 73225) and that a microsurgical team is available — DIEP is a microsurgical procedure requiring operative times of 6–10 hours, and payers may scrutinize facility authorization as well as surgeon authorization.

Functional Blepharoplasty Prior Authorization: Visual Field Criteria

Blepharoplasty (CPT 15822 upper lid, 15823 upper lid with excessive skin weighing down lid, 15820 lower lid) is one of the most frequently prior-authorized plastic surgery procedures and one of the most frequently denied — because payers have specific, measurable visual field criteria and a large proportion of submitted requests do not meet those criteria or do not include the required objective testing.

For functional blepharoplasty to qualify as reconstructive (covered by insurance), the patient must demonstrate that bilateral upper eyelid dermatochalasis (excess skin) occludes a defined portion of the superior visual field. The standard criterion — used by Medicare, most Blue Cross plans, Aetna, Cigna, and United — is that the redundant skin must obstruct the superior visual field at 30 degrees or above on Humphrey visual field testing, with and without the lid taped up (to isolate the skin contribution versus the levator function).

The prior auth documentation package for functional blepharoplasty must include: (1) Humphrey Visual Field (HVF) 24-2 or 30-2 testing results showing the degree of superior field obstruction — submit the printout, not just a summary; (2) standardized pre-operative photographs showing redundant skin resting on the eyelashes or obscuring the visual axis (photograph taken in primary gaze, natural lighting, no brow elevation); (3) documentation of functional symptoms (difficulty reading, driving, or performing ADLs due to visual obstruction — not cosmetic complaints); (4) MRD-1 measurement (margin reflex distance — distance from the corneal light reflex to the upper eyelid margin, normal ≥4mm) to distinguish blepharoptosis (ptosis repair, CPT 67903–67908) from dermatochalasis (blepharoplasty).

For patients with concomitant ptosis, submit authorization requests for both the blepharoplasty and the ptosis repair separately. Many payers require a separate auth for each procedure code and may cover one but not the other. Document the clinical reasoning for each code — do not assume that authorization for blepharoplasty implies authorization for ptosis repair in the same session.

Reduction Mammaplasty Prior Authorization: Schnur Scale and BMI Criteria

Reduction mammaplasty (CPT 19318) is covered by most commercial payers when the procedure meets clinical criteria for reconstructive necessity — primarily macromastia causing documented physical symptoms. However, the specific criteria vary significantly by payer, and the Schnur Sliding Scale (also called the Schnur scale) remains the most widely used benchmark despite clinical controversy about its predictive validity.

The Schnur scale correlates a patient's body surface area (BSA, calculated from height and weight) with the minimum grams of breast tissue that must be removed per breast to qualify for coverage. For a patient with a BSA of 1.7 m², the typical Schnur minimum is approximately 500–600 grams per breast. For a BSA of 2.0 m², the minimum rises to approximately 700–800 grams. Submit a BSA calculation (can be calculated from height and weight using the Mosteller formula) and a stated expected resection weight in your prior auth request. The operative note must then confirm that the actual resection weight met or exceeded the stated minimum — if it falls short, a post-hoc denial is possible.

Beyond the Schnur scale, document the patient's physical symptoms attributed to macromastia: chronic neck pain (cervical spine X-rays documenting degenerative changes, if available), shoulder groove formation from bra straps (photograph), upper back pain with documented treatment (PT records, chiropractic records, NSAID use), skin rash or intertrigo beneath the breast fold (photograph with dermatology co-management if treated), and documented difficulty with exercise or ADLs. The more objective the documentation, the stronger the authorization request.

BMI criteria vary by payer: some plans (notably some Blue Cross plans and Cigna policies) require a BMI below 27–30 for coverage, arguing that weight loss should be pursued first. For patients above the BMI threshold, submit documentation of weight management attempts (bariatric referral, documented diet counseling, weight history) and an argument that the macromastia symptoms are disproportionate to the BMI and will not resolve with weight loss alone. A letter from the patient's PCP supporting the medical necessity of the reduction and confirming weight management attempts strengthens this argument significantly.

Functional Rhinoplasty Prior Authorization: Septoplasty and Turbinate Reduction

Functional rhinoplasty — surgical correction of nasal airway obstruction — overlaps with otolaryngology prior authorization in practice, as both plastic surgeons and ENT surgeons perform septoplasty and inferior turbinate reduction. When a plastic surgeon performs combined functional and cosmetic rhinoplasty, the prior authorization must separate the functional and cosmetic components clearly, as the functional portion may be covered while the cosmetic component is not.

Septoplasty (CPT 30520) corrects a deviated nasal septum that obstructs the internal nasal valve or nasal airway. Prior auth documentation requires: nasal endoscopy or structured physical exam findings documenting the degree and location of septal deviation (anterior vs. posterior, cartilaginous vs. bony), patient's symptom burden (nasal obstruction severity, Nasal Obstruction Symptom Evaluation (NOSE) score, snoring, sleep disruption, exercise limitation), duration of symptoms (typically require 3+ months documented), and failure of medical management (intranasal corticosteroids such as fluticasone 50mcg or mometasone 50mcg for 4–8 weeks, trial of decongestants, allergy evaluation and management if indicated).

Inferior turbinate reduction (CPT 30130 excision, 30140 submucous resection, or 30802 ablation) is typically authorized concurrently with septoplasty when turbinate hypertrophy contributes to obstruction. Document the turbinate size (moderate or severe hypertrophy on examination) and the response (or lack thereof) to topical steroid treatment.

For combined functional-cosmetic rhinoplasty, submit the authorization for the functional component (septoplasty, 30520) separately from the surgical scheduling of the cosmetic rhinoplasty (CPT 30400–30462). Many payers will authorize the septoplasty but not the cosmetic rhinoplasty, requiring the cosmetic fee to be collected from the patient. The plastic surgeon must quote the patient a blended fee that accounts for this split — the insurance payment covers the functional portion, and the patient pays the cosmetic facility fee, surgeon fee increment, and any cosmetic-specific anesthesia time.

Authorization Request Submission Best Practices

The mechanics of prior authorization submission for plastic surgery reconstructive cases are as important as the clinical documentation content. A complete, well-organized submission package reduces requests for additional information (RFIs), accelerates payer review, and improves first-submission approval rates.

For post-mastectomy reconstruction, the ideal submission package contains: the authorization request form (via payer portal or fax — confirm which the payer requires), a typed letter of medical necessity (not a checkbox form), the mastectomy operative report, pathology report from the mastectomy, photos of the current chest wall, and the proposed operative plan with CPT codes and the planned timeline (immediate vs. delayed, single-stage vs. two-stage).

For functional blepharoplasty: authorization request form, letter of medical necessity with specific reference to the visual field testing results, the HVF printout (scanned as a PDF, clearly labeled with patient identifying information), pre-op photographs (minimum 2 photos: front-facing with natural gaze, showing eyelid skin position relative to the lash line), and ICD-10 codes H02.33x–H02.34x (dermatochalasis by lid and laterality).

For reduction mammaplasty: authorization request, letter of medical necessity with BSA calculation and estimated resection weight, photographs (frontal and bilateral lateral views), symptom documentation (PT records, chiropractic records, dermatology notes for breast fold rash), and the proposed ICD-10 code N62 (hypertrophy of breast).

Fax vs. portal submissions: Increasingly, payers are requiring portal submission rather than fax — and many are building AI-assisted initial review into their portals that can flag incomplete submissions before a human reviewer even sees the case. Submit through the payer-required channel, confirm receipt, and log the submission reference number in your auth tracking system. If using a clearinghouse or auth management platform, verify that your submission includes all attachments — document drops that fail silently (attachment not uploaded properly) are a common source of unnecessary denials.

Appeals and Peer-to-Peer Reviews for Reconstructive Cases

When a reconstructive plastic surgery prior authorization is denied, the appeal process is a structured administrative right — not an optional effort. For high-value reconstructive cases (DIEP flap reconstruction, multi-stage breast reconstruction, complex scar revision), pursuing a peer-to-peer review and formal appeal is almost always worth the physician time investment.

Peer-to-peer review (also called a physician-to-physician review or clinical appeal) is a telephone call between the treating plastic surgeon and the payer's medical director or contracted reviewing physician. The call is typically 15–20 minutes and allows the surgeon to present the case directly, address the specific denial reason, and advocate for the patient. Peer-to-peer calls reverse initial denials in 45–65% of cases for reconstructive surgery — a success rate that makes them the highest-ROI appeals tool available.

To request a peer-to-peer, call the payer's prior authorization line within 24–48 hours of receiving the denial and request a peer-to-peer review. Most payers have a specific department (utilization management) that schedules these calls within 1–3 business days. Prepare a concise case summary: patient diagnosis, procedure proposed, the specific clinical criteria the patient meets, and a direct rebuttal of the stated denial reason. If the denial cites "insufficient conservative management," have the dates and durations of all conservative treatments in front of you during the call.

For cases where peer-to-peer does not reverse the denial, file a formal Level 1 appeal within the payer's required timeframe (typically 30–60 days from denial date for commercial payers, 60 days for Medicare Advantage). The Level 1 appeal should include all original submission documentation plus a formal letter of appeal specifically rebutting the denial rationale with clinical evidence. For reconstructive cases involving WHCRA mandate violations, include a specific reference to the federal mandate — payers have legal obligations to cover WHCRA-mandated procedures and a denial that violates WHCRA should be escalated to the state insurance commissioner if Level 1 appeal fails.